Enfuvirtide antiretroviral therapy in HIV-1 infection

Christina M.R. Kitchen, Miriam A Nuno, Scott G. Kitchen, Paul Krogstad

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

It has been over 25 years since the first diagnosis of what would be known as AIDS. Although great strides in anti-HIV therapeutics have been made, there is still a great need for antiretrovirals that are effective against drug-resistant HIV. Enfuvirtide (ENF) is the first of a new class of fusion inhibitors to be approved by the US Food and Drug Administration for use in combination with other antiretroviral agents among HIV-1 infected patients with previous treatment experience. The inclusion of enfuvirtide in an optimized antiretroviral background regimen for the treatment of HIV-1 infected (treatment-experienced) patients followed the success of two critical clinical trials (TORO: T20 vs Optimized Regimen Only I and II). Even though injection-site reactions persisted in these trials, improved virological and immunological responses were observed among patients. Challenges associated with ENF treatment include the high cost of the drug, injection-site reactions, determining the optimal time to initiate treatment, and the potential for the selection of drug resistant mutants and viral evolution. ENF is a promising novel treatment for HIV infected individuals whose choices for effective treatment are limited by previous treatment and resistance. Understanding the implications of viral fitness and evolution in the presence of ENF treatment is crucial in determining effective and safe treatment regimens, particularly among treatment-experienced patients.

Original languageEnglish (US)
Pages (from-to)433-439
Number of pages7
JournalTherapeutics and Clinical Risk Management
Volume4
Issue number2
StatePublished - May 28 2008
Externally publishedYes

Fingerprint

Patient treatment
HIV Infections
HIV-1
drug
Fusion reactions
fitness
Pharmaceutical Preparations
Anti-Retroviral Agents
AIDS
Therapeutics
inclusion
Costs
HIV
costs
enfuvirtide
experience
Injections
Drug Costs
United States Food and Drug Administration

Keywords

  • Drug resistance
  • Enfuvirtide
  • Evolution
  • gp41
  • HIV
  • Salvage therapy

ASJC Scopus subject areas

  • Medicine(all)
  • Safety Research
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Chemical Health and Safety
  • Pharmacology (medical)

Cite this

Kitchen, C. M. R., Nuno, M. A., Kitchen, S. G., & Krogstad, P. (2008). Enfuvirtide antiretroviral therapy in HIV-1 infection. Therapeutics and Clinical Risk Management, 4(2), 433-439.

Enfuvirtide antiretroviral therapy in HIV-1 infection. / Kitchen, Christina M.R.; Nuno, Miriam A; Kitchen, Scott G.; Krogstad, Paul.

In: Therapeutics and Clinical Risk Management, Vol. 4, No. 2, 28.05.2008, p. 433-439.

Research output: Contribution to journalReview article

Kitchen, CMR, Nuno, MA, Kitchen, SG & Krogstad, P 2008, 'Enfuvirtide antiretroviral therapy in HIV-1 infection', Therapeutics and Clinical Risk Management, vol. 4, no. 2, pp. 433-439.
Kitchen, Christina M.R. ; Nuno, Miriam A ; Kitchen, Scott G. ; Krogstad, Paul. / Enfuvirtide antiretroviral therapy in HIV-1 infection. In: Therapeutics and Clinical Risk Management. 2008 ; Vol. 4, No. 2. pp. 433-439.
@article{9574866a84374de7b7dc067dd5fce818,
title = "Enfuvirtide antiretroviral therapy in HIV-1 infection",
abstract = "It has been over 25 years since the first diagnosis of what would be known as AIDS. Although great strides in anti-HIV therapeutics have been made, there is still a great need for antiretrovirals that are effective against drug-resistant HIV. Enfuvirtide (ENF) is the first of a new class of fusion inhibitors to be approved by the US Food and Drug Administration for use in combination with other antiretroviral agents among HIV-1 infected patients with previous treatment experience. The inclusion of enfuvirtide in an optimized antiretroviral background regimen for the treatment of HIV-1 infected (treatment-experienced) patients followed the success of two critical clinical trials (TORO: T20 vs Optimized Regimen Only I and II). Even though injection-site reactions persisted in these trials, improved virological and immunological responses were observed among patients. Challenges associated with ENF treatment include the high cost of the drug, injection-site reactions, determining the optimal time to initiate treatment, and the potential for the selection of drug resistant mutants and viral evolution. ENF is a promising novel treatment for HIV infected individuals whose choices for effective treatment are limited by previous treatment and resistance. Understanding the implications of viral fitness and evolution in the presence of ENF treatment is crucial in determining effective and safe treatment regimens, particularly among treatment-experienced patients.",
keywords = "Drug resistance, Enfuvirtide, Evolution, gp41, HIV, Salvage therapy",
author = "Kitchen, {Christina M.R.} and Nuno, {Miriam A} and Kitchen, {Scott G.} and Paul Krogstad",
year = "2008",
month = "5",
day = "28",
language = "English (US)",
volume = "4",
pages = "433--439",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",
number = "2",

}

TY - JOUR

T1 - Enfuvirtide antiretroviral therapy in HIV-1 infection

AU - Kitchen, Christina M.R.

AU - Nuno, Miriam A

AU - Kitchen, Scott G.

AU - Krogstad, Paul

PY - 2008/5/28

Y1 - 2008/5/28

N2 - It has been over 25 years since the first diagnosis of what would be known as AIDS. Although great strides in anti-HIV therapeutics have been made, there is still a great need for antiretrovirals that are effective against drug-resistant HIV. Enfuvirtide (ENF) is the first of a new class of fusion inhibitors to be approved by the US Food and Drug Administration for use in combination with other antiretroviral agents among HIV-1 infected patients with previous treatment experience. The inclusion of enfuvirtide in an optimized antiretroviral background regimen for the treatment of HIV-1 infected (treatment-experienced) patients followed the success of two critical clinical trials (TORO: T20 vs Optimized Regimen Only I and II). Even though injection-site reactions persisted in these trials, improved virological and immunological responses were observed among patients. Challenges associated with ENF treatment include the high cost of the drug, injection-site reactions, determining the optimal time to initiate treatment, and the potential for the selection of drug resistant mutants and viral evolution. ENF is a promising novel treatment for HIV infected individuals whose choices for effective treatment are limited by previous treatment and resistance. Understanding the implications of viral fitness and evolution in the presence of ENF treatment is crucial in determining effective and safe treatment regimens, particularly among treatment-experienced patients.

AB - It has been over 25 years since the first diagnosis of what would be known as AIDS. Although great strides in anti-HIV therapeutics have been made, there is still a great need for antiretrovirals that are effective against drug-resistant HIV. Enfuvirtide (ENF) is the first of a new class of fusion inhibitors to be approved by the US Food and Drug Administration for use in combination with other antiretroviral agents among HIV-1 infected patients with previous treatment experience. The inclusion of enfuvirtide in an optimized antiretroviral background regimen for the treatment of HIV-1 infected (treatment-experienced) patients followed the success of two critical clinical trials (TORO: T20 vs Optimized Regimen Only I and II). Even though injection-site reactions persisted in these trials, improved virological and immunological responses were observed among patients. Challenges associated with ENF treatment include the high cost of the drug, injection-site reactions, determining the optimal time to initiate treatment, and the potential for the selection of drug resistant mutants and viral evolution. ENF is a promising novel treatment for HIV infected individuals whose choices for effective treatment are limited by previous treatment and resistance. Understanding the implications of viral fitness and evolution in the presence of ENF treatment is crucial in determining effective and safe treatment regimens, particularly among treatment-experienced patients.

KW - Drug resistance

KW - Enfuvirtide

KW - Evolution

KW - gp41

KW - HIV

KW - Salvage therapy

UR - http://www.scopus.com/inward/record.url?scp=44149117693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44149117693&partnerID=8YFLogxK

M3 - Review article

VL - 4

SP - 433

EP - 439

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

IS - 2

ER -